SS-31

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial

Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial

Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism

In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy

Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial

The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction

Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy

Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide

Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis

Effects of Single Vs. Multiple Sets during 10 Weeks of Water-based Resistance Training on Neuromuscular Adaptations in Young Women

Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects

Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome

Potent mitochondria-targeted peptides reduce myocardial infarction in rats

Antibodies to pancreatic duct cells in Sjögren's syndrome and rheumatoid arthritis

Reduction of early reperfusion injury with the mitochondria-targeting peptide bendavia

Elamipretide: First Approval

Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential

Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects

Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide

SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease

Targeting mitochondrial dysfunction with elamipretide

Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid

Mitochondrial dysfunction and beneficial effects of mitochondria-targeted small peptide SS-31 in Diabetes Mellitus and Alzheimer's disease

Neuroprotective Effects of a Small Mitochondrially-Targeted Tetrapeptide Elamipretide in Neurodegeneration

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

Treatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice

Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice